Analytical Data
-
Gene name
MYLK4
- Application
-
Alternative Names
SgK085; caMLCK like; Novel Myosin Light Chain Kinase; Sugen kinase 85
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5SUV5
-
Expression Region
Ala96~Ser353
-
Molecular Weight
60kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYLK4, or myosin light chain kinase 4, is a serine/threonine kinase that plays a crucial role in various cellular processes, including muscle contraction and cell motility. As a member of the myosin light chain kinase family, MYLK4 is primarily expressed in smooth muscle and has emerged as a significant player in cardiovascular biology, particularly in the regulation of vascular smooth muscle tone. The understanding of MYLK4's function has been further enhanced by recent studies suggesting its involvement in various pathological conditions such as hypertension and atherosclerosis. Due to its potential therapeutic implications, researchers are increasingly focused on characterizing MYLK4 at a molecular level, exploring its biochemical properties, regulatory mechanisms, and interactions with other proteins. The investigation of MYLK4 recombinant proteins aims to provide insights into its structure-function relationships and develop targeted interventions that modulate its activity. Given the rising prevalence of cardiovascular diseases globally, the understanding and manipulation of MYLK4 may offer novel strategies for treatment and prevention, thus underscoring the importance of continued research in this area.
